People

Mallory Johnson, PhD

Faculty Director, CFAR
Medicine

I am a licensed clinical health psychologist, whose research has focused on understanding, measuring, and improving the health of patients with chronic diseases such as HIV. My program of multidisciplinary collaborative research is focused on improving HIV treatment outcomes through patient empowerment. My teaching mission is primarily achieved through my mentoring of early career investigators. I am the Co-Director of the NIH-funded Center for AIDS Prevention Studies (CAPS) and am Director the the CAPS Developmental Core.

Gretchen Kiser, PhD

Executive Director
Research Development Office

Dr. Gretchen Kiser is the Executive Director of the Research Development Office (RDO) at the University of California San Francisco.

Kenneth Laslavic

Senior Senate Analyst
E_Acad Sen Committee Supp

Pui Yee Law

Assistant Program Director
M_Ortho-Gen Ortho-Core

Michael Lee

Executive Director
Vice Chanc Research

Jonathan Leff

Administrative Director
M_Cardiovascular Research Inst

Mary Nakamura, MD

PROF IN RES-HCOMP
Precision Medicine in Rheumatology PREMIER

Mary Nakamura received her B.A. from Swarthmore College, her M.D. from Yale and trained in internal medicine at the University of California, San Francisco. She completed her rheumatology training at Johns Hopkins and UCSF. She did her post doctoral work at UCSF under the mentorship of Bill Seaman. She is a basic-translational researcher focused on studies in the field of osteoimmunology. She leads the Rheumatoid Arthritis Clinic at UCSF Parnassus and is a clinical attending at the SF VA HCS.

Nathaniel Prorok, MHA

Program Coordinator
Innovation Ventures

Katherine Rankin, PhD

RAP Chairman
Director
ADRC

Philip Rosenthal, MD

Faculty Director, REAC
Medicine

We have three main areas of interest, all involving malaria, one of the most important infections of humans. First, we study the basic biology of malaria parasites, including the biochemical properties and biological roles of parasite proteases and mechanisms of action of novel antimalarial agents. Second, in collaboration with industry and academic groups, we are pursuing drug discovery, evaluating protease inhibitors, oxaboroles, and other compounds as potential antimalarial drugs.

Mariana Salles La Terza Velleca, MS, BSPharm

TB RAMP Program Coordinator
M_MED-ZSFG-PULM

Brenda Sanchez

Program Analyst
Medicine

Pages